Assess whether biosimilarity is analytically justified (f2ba2d)

Situation

CMC and Development Pathways work in a labeling team facing a boxed-warning debate now turns on biosimilarity is analytically justified because an AdCom briefing document that overstates subgroup findings put disproportionate reporting signal workbook in play. 505(b)(2) development lead should say what disproportionate reporting signal workbook proves.

Decision

505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Authorize Proceed under protocol now; disproportionate reporting signal workbook already has the discriminator after an AdCom briefing document that overstates subgroup findings.
• Keep Pause the pathway in force until disproportionate reporting signal workbook is completed after an AdCom briefing document that overstates subgroup findings for 505(b)(2) development lead.
• Treat disproportionate reporting signal workbook as Escalate safety review because both readings appear after an AdCom briefing document that overstates subgroup findings.
• Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the page biosimilarity is analytically justified turns on in disproportionate reporting signal workbook.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• For this Pharma & Life Sciences CMC and Development Pathways file, read disproportionate reporting signal workbook against an AdCom briefing document that overstates subgroup findings and write the one fact that would move biosimilarity is analytically justified for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings). The follow-on CMC and Development Pathways action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.